MWM
NKTR icon

Maltin Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Maltin Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-867
Closed -$8.84K – 137
2025
Q1 		$8.84K Hold
867
– – ﹤0.01% 130
2024
Q4 		$12.1K Hold
867
– – 0.01% 129
2024
Q3 		$16.9K Hold
867
– – 0.01% 125
2024
Q2 		$16.1K Hold
867
– – 0.01% 119
2024
Q1 		$12.1K Hold
867
– – 0.01% 120
2023
Q4 		$7.34K Hold
867
– – ﹤0.01% 117
2023
Q3 		$7.74K Hold
867
– – 0.01% 110
2023
Q2 		$7.48K Hold
867
– – 0.01% 106
2023
Q1 		$9.14K Buy
+867
New +$26.2K 0.01% 103

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Maltin Wealth Management's NKTR Position: Q2 2025 in Review

Maltin Wealth Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 867 shares — an estimated $8.84K sold.

Maltin Wealth Management first reported a position in NKTR in Q1 2023 and held it in 9 quarters. The position peaked at $16.9K in Q3 2024. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Maltin Wealth Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Maltin Wealth Management sold 867 Nektar Therapeutics shares in Q2 2025, an estimated $8.84K.
  • Maltin Wealth Management first reported a position in Nektar Therapeutics in Q1 2023 and held it in 9 quarters.
  • Maltin Wealth Management's Nektar Therapeutics position peaked at $16.9K in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Maltin Wealth Management's 13F filing for Q2 2025, filed 6 Aug 2025.